Ovarian cancer is burdened by the highest mortality rate among gynecological cancers. Gold standard is represented by the association of platinum-taxane -based chemotherapy and radical surgery. Despite several adjustments occurred in cytotoxic drug in last decades, most patients continue to relapse, and no significant enhancement has been reached in the overall survival. The development of drug resistance and the recurrence of disease have prompted the investigations of other targets that can be used in the treatment of ovarian cancers. Among such targets, polyadenosine diphosphate-ribose polymerase (PARP) represents a novel way to target specific patways involved in tumor growth. PARP accelerates the reaction of the polyADP-ribosylation of proteins implicated in DNA repair. PARP inhibitors have shown activity in cancers with BRCA mutations, with other deficient DNA repair genes or signaling pathways that modulate DNA repair, or in association with DNA damaging agents not involved in DNA repair dysfunction. A number of inhibitors for PARP has been developed, and such drugs are under investigation in clinical trials to identify their impact in the treatment of ovarian cancers. This review aims to summarize the recent researches and clinical progress on PARP inhibitors as novel target agents in ovarian cancer.

PARP inhibition: a promising therapeutic target in ovarian cancer / Musella, Angela; Marchetti, Claudia; Gasparri, Marialuisa; Salerno, Laura; Casorelli, Assunta; Domenici, Lavinia; Imperiale, Ludovica; Ruscito, Ilary; Abdul Halim, T; Palaia, Innocenza; DI DONATO, Violante; Pecorini, Francesco; Monti, Marco; Muzii, Ludovico; BENEDETTI PANICI, Pierluigi. - In: CELLULAR AND MOLECULAR BIOLOGY. - ISSN 1165-158X. - STAMPA. - 61:6(2015), pp. 44-61. [10.14715/cmb/2015.61.6.8]

PARP inhibition: a promising therapeutic target in ovarian cancer

MUSELLA, ANGELA;MARCHETTI, CLAUDIA;GASPARRI, MARIALUISA;SALERNO, LAURA;CASORELLI, ASSUNTA;DOMENICI, LAVINIA;IMPERIALE, LUDOVICA;RUSCITO, ILARY;PALAIA, INNOCENZA;DI DONATO, VIOLANTE;PECORINI, Francesco;MONTI, Marco;MUZII, LUDOVICO;BENEDETTI PANICI, PIERLUIGI
2015

Abstract

Ovarian cancer is burdened by the highest mortality rate among gynecological cancers. Gold standard is represented by the association of platinum-taxane -based chemotherapy and radical surgery. Despite several adjustments occurred in cytotoxic drug in last decades, most patients continue to relapse, and no significant enhancement has been reached in the overall survival. The development of drug resistance and the recurrence of disease have prompted the investigations of other targets that can be used in the treatment of ovarian cancers. Among such targets, polyadenosine diphosphate-ribose polymerase (PARP) represents a novel way to target specific patways involved in tumor growth. PARP accelerates the reaction of the polyADP-ribosylation of proteins implicated in DNA repair. PARP inhibitors have shown activity in cancers with BRCA mutations, with other deficient DNA repair genes or signaling pathways that modulate DNA repair, or in association with DNA damaging agents not involved in DNA repair dysfunction. A number of inhibitors for PARP has been developed, and such drugs are under investigation in clinical trials to identify their impact in the treatment of ovarian cancers. This review aims to summarize the recent researches and clinical progress on PARP inhibitors as novel target agents in ovarian cancer.
2015
ovarian cancer; PARP inhibitors; target therapies; synthetic lethality 1
01 Pubblicazione su rivista::01a Articolo in rivista
PARP inhibition: a promising therapeutic target in ovarian cancer / Musella, Angela; Marchetti, Claudia; Gasparri, Marialuisa; Salerno, Laura; Casorelli, Assunta; Domenici, Lavinia; Imperiale, Ludovica; Ruscito, Ilary; Abdul Halim, T; Palaia, Innocenza; DI DONATO, Violante; Pecorini, Francesco; Monti, Marco; Muzii, Ludovico; BENEDETTI PANICI, Pierluigi. - In: CELLULAR AND MOLECULAR BIOLOGY. - ISSN 1165-158X. - STAMPA. - 61:6(2015), pp. 44-61. [10.14715/cmb/2015.61.6.8]
File allegati a questo prodotto
File Dimensione Formato  
Musella_PARP-inhibition-therapeutic_2015.pdf

accesso aperto

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 641.13 kB
Formato Adobe PDF
641.13 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/873003
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 24
social impact